Why is there no sales of Obeticholic acid in the domestic market for the time being?

Obeticholic acid is a farnesoid Although the drug has been approved and widely used in the international market, it has not yet been officially launched in the Chinese domestic market, and patients can only purchase it through overseas channels. This current situation is mainly caused by many factors.

Obeeticholic acid has not yet passed the approval process of the National Medical Products Administration of China (NMPA). Before drugs enter the Chinese market, they must go through strict clinical trial data submission and review procedures to ensure the safety, effectiveness and quality control of the drugs. Due to the long approval cycle and the fact that some foreign marketed drugs require additional clinical studies on Chinese patients, the domestic launch of obeticholic acid has been delayed.

Obeticholic acid is an innovative drug, and its introduction involves multiple factors such as patent protection, pricing strategies, and medical insurance negotiations. Competition in the domestic drug market is fierce, and the introduction of new drugs often requires comprehensive consideration of patient needs, cost-effectiveness, and medical insurance coverage. At this stage, drug manufacturers may not have completed relevant negotiations or strategic adjustments, resulting in drugs not yet entering the domestic circulation system.

Patients' awareness of the drug and doctors' usage habits also affect its marketing. As an emerging treatment option, obeticholic acid is still in the stage of gradual promotion in the domestic diagnosis and treatment guidelines and physician consensus for related diseases. More clinical practice and expert recommendations are needed to promote its popularization and application.

Regarding price, obeticholic acid has two options: original drug and generic drug in overseas markets. The original version is more expensive, while the generic drugs produced by Mylan India are relatively affordable, usually less than 1,000 yuan per box, making them a viable alternative for economical patients. When patients cannot obtain it directly in China, they may consider obtaining it through regular overseas drug purchase channels to ensure drug safety and drug quality. In the future, with the progress of approval and the growth of market demand, obeticholic acid is expected to gradually enter the domestic market and benefit more patients.

Reference materials:https://www.drugs.com/